An experimental study of the absorption into blood of inhaled plutonium nitrate from the human respiratory tract was conducted. Human respiratory tract model (HRTM) parameters describing the time dependence of absorption were evaluated and compared with similar parameters determined for rats.
INTRODUCTION
One of the main factors that determines the radiation dose from an inhaled radioactive material is the rate at which the material is absorbed from the lungs into blood and then deposited in other organs. In the human respiratory tract model (HRTM) (ICRP, 1994 ) the simplest representation of absorption is described using three parameters: the rapidly absorbed fraction, f r , the rapid absorption rate, s r , and the slow absorption rate, s s . This work, part of an international collaboration (Stradling et al., 2000) , was performed to investigate the absorption of inhaled plutonium nitrate in humans and to evaluate absorption parameters for comparison with values determined for the same aerosol inhaled by other mammalian species. This interspecies comparison should thus improve the scientific basis for predicting the biokinetics of inhaled radionuclides in humans from the results of animal studies.
MATERIALS AND METHODS
Two healthy male volunteers with normal respiratory function were recruited by procedures authorized by an independent ethics committee, following its reviews of the study's objectives, justification and experimental design and of the anticipated committed effective dose (80 µSv). Low doses were achievable because tracers of high isotopic purity were used. These were 237 Pu, which has a half-life of 45.3 days and decays by electron capture and is thus quantifiable in samples and in vivo through its K X-ray emissions, and 244 Pu, which has a half-life of 8.3 × 10 7 yr and is measurable in samples by mass spectrometry.
A mixed 237 Pu/ 244 Pu nitrate aerosol was generated from a 0.5% sodium nitrate, 0.01 M nitric acid solution containing these tracers. The nebulized droplets were dried rapidly to produce an aerosol of 1.1 µm median aerodynamic diameter and geometric standard deviation (σ g ) ∼1.2. The subjects inhaled the aerosol for 25-30 min, adopting a controlled breathing pattern with the aerosol injected as a bolus at the beginning of each breath so as to maximize alveolar deposition. Retention in the lungs and other organs was measured by external counting using collimated germanium semiconductor detectors up to 120 days after inhalation, and 237 Pu in urine and faecal samples was also measured over the same period. The accelerator mass spectrometry (AMS) technique will enable measurements of 244 Pu in blood and excreta samples to be continued for many years.
RESULTS AND DISCUSSION
Only part of the data acquired so far can be shown here. All 237 Pu data is decay-corrected to the time of inhalation. Lung retention and liver uptake/retention of 237 Pu for one of the subjects are shown in Fig. 1 , which also shows multi-exponential fits to the data. In both subjects an earlier study had shown that 80-90% of i.v. injected 237 Pu was taken up by the liver within several weeks (Newton et al., 1998) . The liver retention data therefore provide a good indication of cumulative uptake. Figure 2 shows the amounts of 237 Pu and 244 Pu in blood for both subjects, derived from the measured concentrations and the subjects' estimated blood volumes. Multi-exponential fits to the data are also shown. This figure demonstrates the value of the additional data provided by AMS. 237 Pu was detectable by X-ray spectrometry only from 2 h to 10 days after inhalation, whereas the virtual absence of radioactive decay of 244 Pu and its ready detectability at femtogram levels have widened the period of study to ∼15 min to 750 days. The maximum concentration in blood would occur only a few minutes after inhalation if the rapid rate constant (s r ) was similar to that for Type M material (i.e. 100 per day). The maxima in Fig. 2 appear at ∼1.5 days, showing that s r must be much lower. Differences in the height of the peak for the two subjects arise mainly from differences in their rates of uptake by the liver (Newton et al., 1998) . HRTM parameters describing absorption have been determined from the retention and excretion data and from data on the biokinetic behaviour of 237 Pu previously given i.v. to these subjects (Talbot et al., 1997) . Provisional values of the parameters are shown in Table 1 , together with values determined in rats (Bailey et al., 1999) and the values for Absorption Type M, which is the default HRTM classification for moderately soluble materials. Figure 3 shows the corresponding cumulative amounts absorbed from the lungs as a function of time for humans, predicted by the HRTM with its default deposition and particle transport parameters. The two subjects show similar absorption behaviour. Between 40 and 120 days, cumulative transfer appears similar for man and rats, although the agreement is poorer at earlier times, mainly because of the difference in s r values (Table 1) .
The results of this and other human studies will be used to develop methods for the extrapolation of the results of biokinetic studies with laboratory animals to man. Fig. 3 . Cumulative Pu lung to blood transfer for humans, predicted by the HRTM using experimentally determined absorption parameters for human subjects and rats and default deposition and particle transport parameters. Downloaded from https://academic.oup.com/annweh/article-abstract/46/suppl_1/350/317640 by guest on 29 January 2019
